Viking oral weight loss drug shows promising Phase 1 data

SAN ANTONIO — Viking Therapeutics' highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted weight loss of 6.8% after four weeks, sticking the biotech near the front of a field trying to develop ...